XML 23 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Long-Term Investments (Details)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Aug. 31, 2017
Ownership percentage     73.00%
Braingenesis Biotechnology Co.Ltd [Member]      
Ownership percentage 0.17% 0.17%  
Accounting treatment Cost Method    
Genepharm Biotech Corporation [Member]      
Ownership percentage 0.72% 0.72%  
Accounting treatment Cost Method    
BioHopeKing Corporation [Member]      
Ownership percentage 7.13% 7.13%  
Accounting treatment Cost Method    
BioFirst Corporation [Member]      
Ownership percentage 15.89% 15.84%  
Accounting treatment Equity Method    
Rgene Corporation [Member]      
Ownership percentage 31.61% 31.62%  
Accounting treatment Equity Method